Want to see AU:IDT full AI Analyst Report?
IDT Stock Chart & Stats
AU$0.05
>-AU$0.01(-1.87%)
At close: 4:00 PM EST
AU$0.05
>-AU$0.01(-1.87%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.06
Previous CloseN/A
Volume22.00K
Average Volume (3M)118.08K
Market Cap
AU$15.72M
Enterprise ValueAU$22.36M
Total Cash (Recent Filing)AU$2.52M
Total Debt (Recent Filing)AU$10.82M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Feb 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.27%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding429,816,770
10 Day Avg. Volume126,363
30 Day Avg. Volume118,079
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.70
Price to Sales (P/S)0.66
P/FCF Ratio-55.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$32.00M
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe strong recovery from the 2023 revenue trough indicates renewed demand for IDT’s contract development and manufacturing services. Continued growth would improve capacity utilization, support operating leverage, and provide a stronger foundation for restoring profitability over the next several quarters.
Positive Operating Cash FlowThe return to positive operating cash flow is a constructive sign that the recovering business is beginning to convert activity into cash. If sustained, this can reduce reliance on external funding and provide more flexibility to support manufacturing operations and development programs.
Equity Base And Moderate LeverageA meaningful equity base and moderate absolute leverage provide some financial support while IDT works through its profitability challenges. This balance-sheet position may help the company fund operations and absorb execution volatility, although the recent leverage increase limits that advantage.
Bears Say
Persistent Operating LossesIDT remains loss-making despite the revenue recovery, showing that higher activity has not yet translated into sustainable operating profitability. Negative EBIT limits internally generated funding, weakens resilience during periods of lower utilization, and makes the durability of the turnaround uncertain.
Negative Free Cash FlowSlightly negative free cash flow means operating cash generation still does not fully cover investment and other cash requirements. Continued weak conversion could constrain reinvestment, increase dependence on financing, and delay the point at which revenue growth produces durable financial benefits.
Rising Leverage And Weak ReturnsThe increase in leverage reduces financial flexibility at a time when IDT is still generating negative returns on equity. Higher debt relative to the equity base can restrict future capital allocation choices, while negative ROE indicates the company has not yet earned sustainable returns from its resources.
IDT Australia Limited News
IDT FAQ
What was IDT Australia Limited’s price range in the past 12 months?
IDT Australia Limited lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is IDT Australia Limited’s market cap?
IDT Australia Limited’s market cap is AU$15.72M.
When is IDT Australia Limited’s upcoming earnings report date?
IDT Australia Limited’s upcoming earnings report date is Feb 23, 2027 which is in 123 days.
How were IDT Australia Limited’s earnings last quarter?
IDT Australia Limited released its earnings results on Aug 20, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is IDT Australia Limited overvalued?
According to Wall Street analysts IDT Australia Limited’s price is currently Overvalued.
Does IDT Australia Limited pay dividends?
IDT Australia Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of 6.27%. See more information on IDT Australia Limited dividends here
What is IDT Australia Limited’s EPS estimate?
IDT Australia Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IDT Australia Limited have?
IDT Australia Limited has 429,816,770 shares outstanding.
What happened to IDT Australia Limited’s price movement after its last earnings report?
IDT Australia Limited reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went up 7.317%.
Which hedge fund is a major shareholder of IDT Australia Limited?
Currently, no hedge funds are holding shares in AU:IDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDT Australia Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.70%
12-Months-Change
Fundamentals
Return on Equity
-13.81%
Trailing 12-Months
Asset Growth
-5.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
IDT Australia Limited
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Technical Analysis
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―